Evoke Pharma Inc (EVOK)

2.52
NASDAQ : Health Care
Prev Close 2.48
Day Low/High 2.47 / 2.52
52 Wk Low/High 1.35 / 4.55
Avg Volume 65.90K
Exchange NASDAQ
Shares Outstanding 15.39M
Market Cap 38.16M
EPS -1.10
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Evoke Pharma Presents Gimoti Efficacy And Safety Data From Phase 3 Trial As Late Breaker At Digestive Disease Week 2017

Data Demonstrate Gimoti Significantly Improves Symptoms in Women with Moderate to Severe Diabetic Gastroparesis

FDA Exempts Evoke From Requirement For Human Factor Validation Study

Company reaffirms NDA submission by year end 2017

Evoke Provides Additional Data Demonstrating Statistically Significant Benefit For Gimoti In Moderate To Severe Patients In Phase 3 Diabetic Gastroparesis Trial

Evoke Provides Additional Data Demonstrating Statistically Significant Benefit For Gimoti In Moderate To Severe Patients In Phase 3 Diabetic Gastroparesis Trial

Nausea and abdominal pain symptoms significantly reduced in patients with higher symptom severity

Evoke Receives Positive NDA Submission Guidance From US FDA For Gimoti

Evoke Receives Positive NDA Submission Guidance From US FDA For Gimoti

Healthy volunteer bridging study to oral metoclopramide to be completed and submitted in NDA with existing safety and efficacy data

Evoke Pharma (EVOK) Stock Slides in After-Hours Trade Despite Narrower Q2 Loss

Evoke Pharma (EVOK) Stock Slides in After-Hours Trade Despite Narrower Q2 Loss

Evoke Pharma (EVOK) reported a smaller-than-anticipated loss for the 2016 second quarter after Monday's closing bell.

These 5 Stocks Under $10 Are Set to Soar Higher

These 5 Stocks Under $10 Are Set to Soar Higher

Here's a technical look at how to trade five stocks trading for less than $10 a share.

Evoke Pharma (EVOK) Stock Still Slipping After Trial Results

Evoke Pharma (EVOK) Stock Still Slipping After Trial Results

Evoke Pharma (EVOK) shares continue to fall today after the company's diabetic gastroparesis trials missed topline results on Monday.

Evoke Pharma (EVOK) Stock Plummets After Late-Stage Trial Miss

Evoke Pharma (EVOK) Stock Plummets After Late-Stage Trial Miss

Evoke Pharma’s (EVOK) diabetic gastroparesis drug missed its primary endpoint in phase 3 topline results.